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Background: Estrogen metabolism-mediated oxidative stress is suggested to play an important role in
estrogen-induced breast carcinogenesis. We have earlier demonstrated that antioxidants, vitamin C (Vit C) and
butylated hydroxyanisole (BHA) inhibit 17β-estradiol (E2)-mediated oxidative stress and oxidative DNA damage,
and breast carcinogenesis in female August Copenhagen Irish (ACI) rats. The objective of the present study was to
characterize the mechanism by which above antioxidants prevent DNA damage during breast carcinogenesis.
Methods: Female ACI rats were treated with E2; Vit C; Vit C + E2; BHA; and BHA + E2 for up to 240 days. mRNA and
protein levels of a DNA repair enzyme 8-Oxoguanine DNA glycosylase (OGG1) and a transcription factor NRF2
were quantified in the mammary and mammary tumor tissues of rats after treatment with E2 and compared with
that of rats treated with antioxidants either alone or in combination with E2.
Results: The expression of OGG1 was suppressed in mammary tissues and in mammary tumors of rats treated
with E2. Expression of NRF2 was also significantly suppressed in E2-treated mammary tissues and in mammary
tumors. Vitamin C or BHA treatment prevented E2-mediated decrease in OGG1 and NRF2 levels in the mammary
tissues. Chromatin immunoprecipitation analysis confirmed that antioxidant-mediated induction of OGG1 was
through increased direct binding of NRF2 to the promoter region of OGG1. Studies using silencer RNA confirmed
the role of OGG1 in inhibition of oxidative DNA damage.
Conclusions: Our studies suggest that antioxidants Vit C and BHA provide protection against oxidative DNA
damage and E2-induced mammary carcinogenesis, at least in part, through NRF2-mediated induction of OGG1.
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Long-term estrogen use has been associated with the initi-
ation and development of breast cancer [1-7]. The mecha-
nisms of E2-induced breast carcinogenesis are however
not clearly understood. In E2-induced breast carcinogen-
esis, oxidative stress produced by redox cycling between
catechol estrogens and estrogen quinones is implicated to
play an important role [8,9]. 8-Hydroxydeoxyguanosine (8-
OHdG) is one of the most commonly formed DNA lesions* Correspondence: bhath@umkc.edu
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reproduction in any medium, provided the orproduced in response to E2-induced oxidative stress and is
considered as a cellular marker for both oxidative stress and
oxidative DNA damage [3-5]. 8-Hydroxydeoxyguanosine in
DNA is repaired primarily via the DNA base excision re-
pair pathway. 8-Oxoguanine DNA glycosylase is the rate-
limiting enzyme involved in the removal of 8-OHdG from
DNA [10,11]. Association of decreased levels of OGG1
with tumor development and/or progression has been well
established [12,13]. We have earlier reported that two
known prototypic antioxidants Vit C and BHA can in-
hibit E2-mediated breast cancer development in female
ACI rats [2,5,7]. The female ACI rat model is a relevant
model system for human breast cancer as it shares manytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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man sporadic breast cancers, both in early pre-malignant
lesions, as well as in primary tumors [14-19]. The tumors
that develop in this animal model are estrogen dependent,
aneuploid and exhibit genomic instability [14-19].
Protective mechanisms of action of antioxidants are often
ascribed to their ability to act as free radical scavengers
through induction of transcription factor nuclear factor
erythroid 2-related factor 2 (NRF2)-dependent antioxidant
enzymes and/or “phase II” metabolic enzymes involved in
E2-metabolism [5,20,21]. NRF2 is a known regulator of
the antioxidant response [22-25]. NRF2-regulated phase
II enzymes protect against the development of cancer
by catalyzing reactions that convert highly reactive, car-
cinogenic chemicals to less reactive products [22-24,26].
We have recently demonstrated that Vit C and BHA
provide protection against E2-mediated oxidative DNA
damage but the mechanism is not well understood [5].
In order to find a putative mechanism for inhibition of
8-OHdG formation by antioxidants Vit C and BHA, we
have examined the involvement of OGG1 and NRF2.
The human OGG1 promoter contains a putative NRF2
binding site and NRF2 leads to OGG1 transcriptional
activation [27,28]. In this study, we present evidence
that antioxidants, Vit C- and BHA-mediated induction
of NRF2 regulates OGG1 which is involved in the inhib-
ition of E2-induced oxidative DNA damage and possibly
breast carcinogenesis in the rat model of breast cancer.
Methods
Treatment of animals
Female ACI rats (4 weeks of age; Harlan Sprague Dawley,
Indianapolis, IN) were housed under controlled temper-
ature, humidity, and lighting conditions. After a one-week
acclimatization period, rats were divided into following
different groups: Control, E2, BHA, BHA+ E2, Vit C and
Vit C + E2. Rats were implanted subcutaneously with 3 mg
E2 pellets. E2 pellets were prepared in 17 mg cholesterol
as a binder as described previously [29,30]. Control, Vit C
and BHA groups received 17 mg cholesterol pellet only.
Vitamin C (1%) was administered in drinking water. BHA
(0.7%) was fed to animals through phytoestrogen-free
AIN76A diet (Dyets, Bethlehem, PA). Water was given
ad libitum to all the animals. Each of the six treatment
groups were divided into two subgroups, containing at
least 10 rats in each subgroup. Each subgroup under-
went treatments as described above for 7 and 240 days,
respectively. At the end of the experimental time period,
animals were anesthetized using isoflurane and eutha-
nized. Mammary tumors, mammary, liver, lung, kidney,
spleen and uterine tissues were removed and snap fro-
zen in liquid nitrogen for future analyses. The animals
were treated and handled according to the guidelines
of the University Animal Care and Use Committee.Animal protocols used in the current study were approved
by the Institutional Animal Care and Use Committee.
Cell culture
Non-tumorigenic human breast epithelial cell line, MCF-
10A and tumorigenic human breast epithelial cell line,
T47D were obtained from American Type Culture Collec-
tion (ATCC, Manassas, VA). Cells were grown in DMEM/
F12 (50:50) medium (Mediatech, Herndon, VA). Twenty-
four hours before treatment, cells were washed twice with
PBS and then grown in phenol red-free DMEM/F12 (50:50)
medium supplemented with charcoal-dextran stripped
serum. Cells were treated with E2 (10 and 50 nM), Vit C
(250 μM and 1 mM), BHA (250 μM), Vit C + E2, and
BHA + E2 for up to 48 h.
Real-time PCR analysis
Total RNA was isolated from ACI rat tissues and cell lines
using RNeasy lipid tissue kit (Qiagen, Valencia, CA) and
Tri reagent (Molecular Research Center, Inc., Cincinnati,
OH), respectively, according to the supplier’s protocols.
Five microgram total RNA was reverse transcribed using
the superscript II reverse transcription system (Invitrogen,
Carlsbad, CA). Real-time PCR was performed using iCycler
iQ5 system (Bio-Rad Laboratories, Hercules, CA). Rat
and human specific NRF2 QuantiTect primers (Cat #
QT00183617 and QT00027384, respectively), and rat spe-
cific OGG1 QuantiTect primers (Cat # QT00186641) used
in this study were obtained from Qiagen (Valencia, CA).
Human OGG1 specific primers used in this study were
as follows: forward primer 5′-GTGCCCGTTACGTGAGT
GCCAGTGC-3′ and reverse primer 5′-AGAGAAGTGG
GGAATGGAGGGGAAGGTG-3′. Data were analyzed
from at least 5 different animals/cell line samples from
each group. The expression of cyclophilin, a housekeeping
gene, was used for quantification of the mRNA levels of
genes of interest [31].
RNA interference
Small interfering RNAs (siRNAs) for NRF2, OGG1 and
scrambled siRNA were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA). MCF-10A cells were transfected
with siNRF2 (20 nmol/L) or siOGG1 (5 nmol/L) using
Lipofectamine 2000 transfection reagent (Invitrogen) for
48 h. Scrambled siRNA (20 nmol/L) transfected MCF-
10A cells were used as negative controls as described re-
cently [5]. MCF-10A cells transfected with siNRF2 and
siOGG1 were used for western blot and DNA 8-OHdG
analyses, respectively.
Western blot analysis
Approximately 50 mg of different female ACI rat tissues
were homogenized in a tissue protein extraction buffer
(T-PER, Thermo Scientific, Rockford, IL). Lysates from
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tease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
The Pierce BCA Protein Assay kit was used to determine
protein concentrations (Pierce, Rockford, IL). Eighty micro-
gram total protein from ACI rat tissues or 30 μg protein
from cell lines was size fractionated on a 12% SDS-
polyacrylamide gel, and transferred onto a PVDF mem-
brane (Millipore Corp., Billerica, MA) under standard
conditions [4,5,31]. OGG1 (Cat # sc-33181) and NRF2
(Cat # sc-30915) primary antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA) were used for immunodetection.
Chemiluminescent detection was performed using the
BM Chemiluminescence Detection kit (Roche, Indianapolis,
IN) and Alpha Innotech FluorChem HD2 (Alpha Innotech,
San Leandro, CA) gel documentation system. Membranes
were reprobed with α-Tubulin antibody (Santa Cruz
Biotechnology) using the methods described above. Inten-
sities of the bands were quantified and normalized using
AlphaEase FC StandAlone software (version 6.0.0.14; Alpha
Innotech).
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assays were performed
with MCF-10A cells using ChIP Assay Kit (USB Corpor-
ation, Cleveland, OH) as suggested by the manufacturer.
Briefly, MCF-10A (~5 ×108) cells grown in 100 mm tissue
culture dishes were treated with E2 (10 nM), Vit C (1 mM)
or BHA (250 μM) for 45 min and cross-linked with 1%
formaldehyde and then sonicated. Soluble chromatin
was collected and incubated on a rotating platform with
goat polyclonal antibody against NRF2 (Cat # sc-30915,
Santa Cruz Biotechnology), overnight at 4°C. The DNA
was recovered and subjected to real-time PCR analysis
using primers flanking antioxidant responsive element
(ARE) region of the human OGG1 gene promoter. The
OGG1 ARE primers used for the end point real-time
PCR amplification using SYBR green method (Qiagen,
Valencia, CA) were as follows: forward primer 5′-GAGAA
CCCAGAAGAACACAG-3′ and reverse primer 5′-GTGC
TGTTTAACAACCTTCC-3′. Amplification of input chro-
matin before immunoprecipitation at a dilution of 1:50
was used as a positive control. ChIP without any anti-
body served as a negative control. The assays were carried
out three times with three replicates in each experiment.
Agarose gel electrophoresis and Ct (cycle threshold) values
for the amplified products for ChIP DNA and input DNA
samples were used to represent the results.
8-OHdG estimation
8-Hydroxydeoxyguanosine (8-OHdG), an accepted marker
of oxidative stress-mediated DNA damage, was estimated
in control mammary tissues, E2-treated mammary and
mammary tumor tissues as well as in E2-treated, siOGG1-
or scrambled-transfected MCF-10A cells using OxiselectOxidative DNA Damage ELISA kit (Cell Biolabs, San Diego,
CA) as described previously [4,5].
Statistical analyses
Statistical analyses were performed by using Sigma Plot
11.0 (Systat Software, San Jose, CA) and IBM SPSS Statis-
tics 19 software (IBM Inc., Armonk, NY). The unpaired
t-test analysis was used to calculate p values for compar-
isons of OGG1 and NRF2 mRNA and protein levels, and
8-OHdG levels, between treated animals and respective
age-matched controls as well as for comparisons in MCF-
10A cells. Fisher’s exact test was used to compare tumor
incidence between two treatment groups. A p value <0.05
was considered significant.
Results
Estrogen treatment inhibits OGG1 expression
We investigated the effect of E2 treatment on the mRNA
expression of OGG1 during early exposure time to estro-
gen (7 days) and during neoplastic (240 days) stages of
breast cancer development in female ACI rats. Signifi-
cant inhibition of OGG1 mRNA expression by E2 was
demonstrated in mammary tissues of rats treated with
E2 for 7 days and OGG1 mRNA expression further
decreased in mammary tissues as well as in mammary
tumors of rats treated with E2 for 240 days, compared
to age-matched mammary tissues from control animals
(Figure 1A).
We also examined OGG1 mRNA expression in vitro
in non-neoplastic human breast epithelial cell line, MCF-
10A and in neoplastic human breast epithelial cell line,
T47D. A significant decrease in OGG1 mRNA levels in
MCF-10A cells after 6 h of E2 (50 nM) treatment com-
pared to time-matched vehicle-treated MCF-10A cells was
demonstrated (Figure 1B). In contrast to MCF-10A cells,
OGG1 mRNA expression in T47D cells significantly de-
creased after 48 h of E2 treatment (Figure 1B). E2-
mediated decrease in OGG1 protein expression was also
examined in MCF-10A and T47D cells by western blot
analyses. Estrogen (50 nM) treatment significantly de-
creased OGG1 protein expression compared to vehicle-
treatment in MCF-10A and T47D cells after 12 and 48 h
of treatment, respectively (Figure 1C). We observed a
similar inhibitory effect of lower dose of E2 (10 nM) on
OGG1 expression in vitro during our dose-curve analysis
(data not shown).
To examine whether E2-mediated suppression of OGG1
was tissue specific, we performed western blot analyses
with protein samples from liver, kidney, uterus, lung,
spleen, breast and breast tumor tissues from female ACI
rats treated with E2 for 240 days. Estrogen treatment
inhibited protein expression of OGG1 in all the tissues
tested compared to age-matched respective tissues from
control animals (Figures 1D and 2B).
Figure 1 Estrogen treatment inhibits OGG1 expression. (A) Real-time PCR data are presented to show expression of OGG1 mRNA in
mammary tumors and in mammary tissues of rats treated with E2 for 7 and 240 days. These data are reported as an average of fold change
values obtained from at least 5 different animals ± SEM, compared to respective age-matched control mammary tissues. (B) OGG1 mRNA
expression levels in MCF-10A and T47D cells treated with E2 (50 nM) for 6 and 48 h, respectively, presented as fold change versus time-matched
vehicle-treated cells. OGG1 mRNA expression data was normalized to cyclophilin as an internal control. These data are reported as an average of
values obtained from at least 5 different samples ± SEM. (C) Representative western blots for OGG1 protein expression in MCF-10A and T47D cells
treated with E2 (50 nM) for 12 and 48 h, respectively. The bar graphs represent fold change in OGG1 protein expression (mean ± SEM), compared
to time-matched vehicle-treated cells. ‘*’ indicates p value <0.05 compared to respective age- or time-matched control samples. (D) Representative
western blot for OGG1 protein expression in different tissues of female ACI rats treated with E2 for 240 days as described in “Methods” section.
Figure 2 Antioxidants Vit C and BHA prevent estrogen-mediated inhibition of OGG1. (A) Real-time PCR data are presented as a bar graph
to show expression levels of OGG1 mRNA in mammary tumors and mammary tissues of rats treated with E2, Vit C or BHA in presence or absence
of E2 for 240 days as described in “Methods” section. OGG1 mRNA expression data were normalized to cyclophilin as an internal control. These
data are reported as an average of values obtained from at least 5 different animals ± SEM, compared to age-matched control mammary tissues.
(B) Female ACI rats were treated with E2, Vit C or BHA in presence or absence of E2 for 240 days as described in “Methods” section. At the end of
the experiment, mammary tissues and mammary tumors were collected, homogenized and used for OGG1 western blot analysis. The bar graph
represents OGG1 protein fold change (mean ± SEM) in mammary tumors and mammary tissues from at least 5 different animals from each treatment
group compared to age-matched control mammary tissues. ‘*’ indicates p value <0.05 compared to age-matched control mammary tissues.
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We have recently reported that antioxidants Vit C and
BHA inhibit E2-mediated oxidative stress and breast
carcinogenesis in female ACI rats after 240 days of treat-
ment [2,7]. To examine whether antioxidants Vit C and
BHA also protect against E2-mediated suppression of
OGG1, we performed real-time PCR and western blot
analysis with mammary tissues and mammary tumor
samples from rats treated with E2, Vit C or BHA in pres-
ence or absence of E2 for 240 days. While E2 significantly
decreased OGG1 mRNA and protein expression in E2-
treated mammary and mammary tumor tissues compared
to age-matched mammary tissues from control animals;
Vit C or BHA alone or in combination with E2 protected
against E2-mediated decrease in OGG1 and induced its
expression at mRNA as well as protein levels (Figure 2).
Antioxidants-mediated regulation of OGG1 is
NRF2-dependent
Transcription factor NRF2 regulates genes containing anti-
oxidant responsive elements (ARE) in their promoter
regions [5,26,32]. Presence of a putative NRF2 binding
site in the human OGG1 promoter has been reported
[27,28] and presence of NRF2 binding site in rat OGG1
promoter region has also been predicted (http://www.
sabiosciences.com/chipqpcrsearch.php). We examined
whether expression of OGG1 during E2-induced car-
cinogenesis is regulated through NRF2. We have earlier
shown significant suppression of NRF2 protein expression
in E2-treated mammary and mammary tumor tissues
after 240 days of treatment compared to age-matched
control mammary tissues [5,33]. NRF2 mRNA and pro-
tein expression was significantly increased in mammary
tissues of rats treated with Vit C or BHA for 240 days,
either alone or in the presence of E2 compared to
age-matched mammary tissues from control animals
(Figure 3A and 3B).
In parallel with decrease in NRF2 protein expression
(Figure 3B), a significant decrease in OGG1 protein ex-
pression in E2-treated mammary tissues and in mammary
tumors, and an increase in OGG1 protein expression in
mammary tissues of animals treated with Vit C- and BHA
was demonstrated (Figure 2B). A decrease in OGG1 pro-
tein expression after silencing of NRF2 in MCF-10A cells
was demonstrated which indicates NRF2-dependent regu-
lation of OGG1 (Figure 3C). To further confirm whether
suppression of OGG1 after E2 treatment and its induction
after antioxidant treatment was through differential bind-
ing of NRF2 to the ARE present in the promoter region
of OGG1, we carried out ChIP assay using MCF-10A
cells. Following chromatin immunoprecipitation using
anti-NRF2 antibody, DNA was recovered and subjected
to real-time PCR analysis using PCR primers flanking the
ARE region of the human OGG1 gene promoter. Estrogentreatment inhibited the binding of NRF2 to the OGG1
gene promoter as shown by increase in Ct values, whereas
antioxidants Vit C and BHA enhanced NRF2 binding to
the OGG1 promoter as shown by decrease in Ct values
compared to control (Figure 3D).
OGG1 inhibits estrogen-induced oxidative DNA damage
8-Oxoguanine DNA glycosylase is the main enzyme in-
volved in the removal of 8-OHdG from DNA, and thus
suggested to be involved in protection against DNA
damage and subsequent carcinogenesis [10-13]. We have
earlier reported that antioxidants Vit C and BHA prevent
E2-mediated oxidative DNA damage and breast carcino-
genesis (Table 1, [5]). Here, we demonstrate that anti-
oxidants prevent E2-mediated suppression of OGG1
(Figure 2 and Table 1). To further examine whether OGG1
confers protection against DNA damage, we quantified
DNA 8-OHdG levels in MCF-10A cell line after siRNA-
mediated silencing of OGG1. Estrogen treatment (50 nM,
48 h) of MCF-10A cells significantly increased 8-OHdG
levels compared to vehicle-treated controls (Figure 4).
Similarly, a significant increase in 8-OHdG levels in
siOGG1 transfected MCF-10A cells compared to scram-
bled siRNA transfected MCF-10A cells was observed
(Figure 4). Moreover, 8-OHdG levels further increased
in siOGG1-trasfected MCF-10A cells treated with E2
compared to 8-OHdG levels in siOGG1-transfected cells
in the absence of E2 treatment (Figure 4).
Discussion
Prolonged exposure to elevated levels of estrogen has
been implicated in the development of breast cancer
[29,34,35]. Estrogens are known to induce cell growth
and loss of DNA repair capacity of the cells [4,19,36].
Accurate DNA repair is essential for the prevention of
mutations and ultimately, cancer. A number of recent
studies have demonstrated that 8-OHdG, likely induced
by estrogen-metabolism-mediated oxidative stress, is formed
after estrogen exposure and suggested that 8-OHdG may
be associated with estrogen-induced breast carcinogenesis
[3-5]. The 8-OHdG adduct is mainly repaired by base
excision repair (BER) mechanism of the cell [37,38]. 8-
Oxoguanine DNA glycosylase (OGG1), an enzyme of
the BER pathway, is highly specific for the removal of
8-OHdG adducts from all regions of the genome [38].
8-Oxoguanine DNA glycosylase first hydrolyzes the glyco-
sidic bond of 8-OHdG, then cleaves the phosphodiester
bond leaving an AP site, which is repaired by DNA poly-
merase [37,38]. A role of this enzyme in cancer prevention/
progression has been documented [12,13,39].
We have earlier shown that E2 induces oxidative stress
and oxidative DNA damage during breast cancer devel-
opment [1,2,5,7]. Female, ovary-intact ACI rat that we
have used in our study is an established animal model
Figure 3 Prevention of estrogen-mediated suppression of OGG1 by antioxidants is NRF2-dependent. (A) Real-time PCR data (normalized
to internal control cyclophilin) are presented as a bar graph to show expression levels of NRF2 mRNA in mammary tumors and mammary tissues
of rats treated with E2, Vit C or BHA in presence or absence of E2 for 240 days. These data are reported as an average of fold change values
obtained from at least 5 different animals ± SEM, compared to age-matched control mammary tissues. ‘*’ indicates p value <0.05 compared to
respective control mammary tissues. (B) Western blot analyses were carried out to determine protein expression levels of NRF2 in mammary
tumors and mammary tissues of rats treated with E2, Vit C, Vit C + E2, BHA and BHA + E2 for 240 days. The bar graph represents NRF2 protein fold
change (mean ± SEM) in mammary tumors and mammary tissues from at least 5 different animals compared to age-matched control mammary
tissues. ‘*’ indicates p value <0.05 compared to respective, age-matched control mammary tissues. (C) MCF-10A cells were transfected with 20
nmol/L of scrambled siRNA or siNRF2 for 48 h and western blot analysis was carried out using NRF2 antibody. Same membrane was reprobed
with OGG1 and α-Tubulin antibodies. Concomitant with a decrease in NRF2 protein expression, there is a corresponding decrease in OGG1
protein expression. (D) MCF-10A cells were treated with E2 (10 nM), Vit C (1 mM), BHA (250 μM) or vehicle for 45 min, fixed with formaldehyde,
cross-linked, and the chromatin sheared. The chromatin was immunoprecipitated with NRF2 antibody. NRF2 binding to OGG1 promoter was
analyzed by real-time PCR with specific primers for the human OGG1 ARE region. The ARE region of the OGG1 promoter was also amplified from
purified soluble chromatin before immunoprecipitation to show input DNA. Representative ChIP agarose gels and real-time PCR Ct values from
three independent experiments are shown. (ND = not detected).
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reported that the serum E2 levels in control, ovary-intact
ACI rats oscillate between ~20 and 75 pg/ml whereas
the mean level of serum E2 in E2-treated, ovary intact
female ACI rats averaged ~100 pg/ml and remained con-
stant during the course of the study [16]. We have
started E2-treatment of female ACI rats when they were
5–6 weeks old. This age is considered as puberty or
early puberty stage for female rats and the duration of
our study was up to 8 months which represents the fer-
tile period of female rats. It has also been reported thatfemale ACI rats remained in proestrus stage for the dur-
ation of study after E2 implantation [18]. We have also
reported for the first time that antioxidants Vit C and
BHA can prevent E2-induced oxidative stress, oxidative
DNA damage and breast cancer in female ACI rats [2,5,7].
However, very little information is available about the
effects of E2 and antioxidants on DNA damage repair
capacity of the cells during E2-induced breast carcino-
genesis. 8-Oxoguanine DNA glycosylase is a key gene
responsible for repair of oxidative DNA damage [10,11].
Therefore, in the present study, we examined whether
Table 1 OGG1 protein expression, 8-OHdG levels and tumor incidence in female ACI rats after different treatments
Group/ treatment n OGG1 protein expression
(fold change vs. control)
8-OHdG levels
(fold change vs. control)
Tumor incidence (%)
Control 10 1.00 1.00 0
E2 11 0.63* 1.79* 82
Tumor 11 0.21* 2.98* -
BHA 17 1.80* 0.89 0
BHA + E2 17 1.50* 1.23# 24#
Vit C 17 1.45* 0.95 0
Vit C + E2 17 1.31* 1.02# 29#
OGG1 protein expression and DNA 8-OHdG levels are presented in mammary tumors and in mammary tissues from control, E2, BHA, BHA + E2, Vit C and Vit C +
E2-treated rats after 240 days of treatment. Column one lists different treatments each group of animals received. The number of animals per group (n) is listed in
column two. Column three shows OGG1 protein expression as an average of values obtained from at least 5 different animals. Column four shows folds change in
DNA 8-OHdG levels compared to age-matched control mammary tissues. The percent tumor incidence in each treatment group after 240 days of treatment is
listed in column five. ‘*’ indicates a p value <0.05 compared to age-matched control tissues and ‘#’ indicates p value <0.05 compared to E2-treated group.
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age through regulation of OGG1. We have shown that E2
treatment significantly decreased OGG1 mRNA and pro-
tein expressions in the mammary tissues (Figures 1 and 2).
The decrease in OGG1 mRNA expression in mammary
tissues was evident as early as 7 days of E2 treatment and
remained significantly decreased in both mammary tissues
and E2-induced mammary tumors after 240 days of E2-
treatment (neoplastic stage) (Figure 2A). We have demon-
strated that long-term continuous E2 exposure (240 days)
significantly suppressed the expression of OGG1, an en-
zyme involved in oxidative DNA damage repair and thus
may lead to increased DNA damage in mammary tumors
and mammary tissues (Figures 1A, 2, and Table 1). In
our previous report, we have shown that exposure to E2
as early as 7 days can initiate proliferative changes in
the mammary tissues, a progression from normal mam-
mary tissue to proliferative tissue such as atypical ductal
hyperplasia, later progressing to tumor formation andFigure 4 OGG1 inhibits oxidative DNA damage. DNA 8-OHdG
levels in MCF-10A cells treated with E2 (50 nM) or vehicle for 48 h
and in OGG1 knocked down MCF-10A cells are represented as a bar
graph. ‘*’ and ‘#’ indicate p value <0.05 compared to vehicle-treated
control and scrambled-transfected MCF-10A cells, respectively.
‘**’ indicates significant difference (p <0.05) between siOGG1 and
siOGG1 + E2 groups.malignancy [1]. Previous studies also support E2-mediated
differential expression of OGG1 in different tissues of
rat [40]. Increased cell proliferation, and decreased OGG1
and thus, compromised DNA damage repair potential
after 7 days of E2 treatment might be the initial steps
that lead to the accumulation of carcinogenic insults at
later time points.
Inhibition of OGG1 protein expression in other tissues
of rats like liver, kidney, uterus, lung and spleen indi-
cates that E2-mediated inhibition of OGG1 was not tis-
sue specific (Figure 1D). We have earlier shown that E2
induces oxidative stress during breast carcinogenesis [1,2,7]
and redox regulation of OGG1 has also been established
[41]. Thus, E2-induced oxidative stress might be one of the
possible mechanism of regulation of OGG1 during breast
carcinogenesis. Recently, Singh et al. have shown that
estrogen decreases the DNA repair capacity in breast cancer
cells, at least in part, through epigenetic mechanism [36].
Dietary supplementation of antioxidants is suggested
to reduce breast cancer most likely through induction
of antioxidant enzymes and/or “phase II” metabolic en-
zymes but the effects of antioxidants on DNA repair
capacity of the cells are not well understood [5,20,21].
In a previous study, Collins et al. found lower DNA
damage in a human study population after consump-
tion of kiwifruit given as an antioxidant supplement in
the diet, but they could not find any change in expres-
sion of DNA repair-related genes OGG1 and AP endo-
nuclease 1 (APE1) [42]. We have earlier reported that
antioxidants Vit C and BHA can prevent E2-induced
oxidative stress, oxidative DNA damage and breast can-
cer in female ACI rats [2,5,7,33]. Significantly decreased
expression of OGG1 at both mRNA and protein levels
after long term E2 treatment and reversal of this suppres-
sion by Vit C and BHA in our study clearly indicates an
important role of OGG1 in antioxidant-mediated protec-
tion against oxidative DNA damage as well as breast can-
cer (Figure 2 and Table 1). A decreased OGG1 enzyme
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breast cancer phenotype [43]. To the best of our know-
ledge, ours is the first report showing the regulation of
DNA damage repair gene OGG1 by dietary antioxidants
Vit C and BHA.
The promoter region of the OGG1 gene does not have
any canonical ERE and there is no evidence for a direct
regulation of OGG1 expression by E2. However, human
OGG1 promoter contains a putative NRF2 binding site
and NRF2 leads to OGG1 transcription [27,28]. Tran-
scription factor NRF2 is a known regulator of the anti-
oxidant response [22-25]. We have recently shown that
antioxidants Vit C and BHA upregulate expression of
NRF2-regulated protective genes NAD(P)H-quinone oxido-
reductase 1 (NQO1) and superoxide dismutase 3 (SOD3)
in mammary tissues [5,33]. Therefore in this study,
we examined whether the regulation of OGG1 in E2-
induced breast cancer is mediated through transcrip-
tion factor NRF2. We have demonstrated that OGG1 is
regulated via an NRF2-dependent pathway (Figure 3).
Decreased mRNA and protein expression of NRF2 and
OGG1 in E2-treated mammary tissues and in E2-induced
mammary tumors after 240 days of E2 treatment and cor-
responding increased mRNA and protein expression of
these genes after Vit C or BHA treatment suggest NRF2-
mediated regulation of OGG1 (Figures 2, 3A and 3B). De-
creased protein expression of OGG1 in NRF2 knocked
down MCF-10A cells confirmed NRF2-mediated regula-
tion of OGG1 (Figure 3C). Results from ChIP assay with
MCF-10A cells treated with E2, Vit C or BHA further
confirmed E2-mediated decreased and antioxidant-mediated
increased binding of NRF2 to the ARE region of OGG1
promoter and indicate a gene-nutrient interactions
(Figure 3D). These results also suggest that E2-mediated
oxidative stress may be involved in the regulation of
OGG1. Collectively, our results provide evidence for
NRF2-mediated regulation of OGG1 in E2-induced breast
carcinogenesis.
Significant increase in 8-OHdG levels (p < 0.05) in OGG1
knocked down MCF-10A cells compared to vehicle or
scrambled siRNA transfected MCF-10A cells confirmed
the role of OGG1 in prevention of estrogen-induced
oxidative DNA damage (Figure 4). Following E2 treat-
ment, further significant increase in 8-OHdG levels
in siOGG1-transfected cells compared to siOGG1-
transfected cells without E2 treatment confirmed that
the increase in 8-OHdG levels was specific to E2-
induced oxidative damage (Figure 4).
Conclusions
In conclusion, data presented in this manuscript demon-
strate that antioxidants Vit C and BHA not only act as
inducers of the antioxidant enzyme system but also act
as the inducers of the DNA repair capacity. Our findingsfurther suggest that antioxidants Vit C and BHA protect
against oxidative DNA damage and E2-induced mammary
carcinogenesis, at least in part, through NRF2-mediated
induction of OGG1.
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